High-Sensitivity Troponin T Plasma Levels in Patients With Aortic Stenosis (Tyrolean Aortic Stenosis Study-2)
Launched by MEDICAL UNIVERSITY INNSBRUCK · May 15, 2015
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Tyrolean Aortic Stenosis Study-2 (TASS-2) is a clinical trial that is looking at a heart protein called troponin T in patients with a condition known as aortic stenosis. Aortic stenosis occurs when the heart's aortic valve narrows, making it harder for the heart to pump blood. This study aims to understand how slightly elevated levels of troponin T in the blood relate to the health of patients, whether they have symptoms like chest pain or fainting, or if they feel fine.
To be part of this trial, participants need to have been diagnosed with aortic stenosis through an ultrasound of the heart or other medical tests. However, people with recent heart problems, like a heart attack or infections affecting the heart, are not eligible to join. While participating, individuals can expect to undergo assessments that will help researchers learn more about the significance of troponin T levels in managing aortic stenosis. This study is currently recruiting participants of all ages and genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • aortic stenosis detected by echocardiography / invasively
- Exclusion Criteria:
- • acute coronary syndrome
- • endocarditis
About Medical University Innsbruck
The Medical University of Innsbruck is a leading academic institution dedicated to advancing healthcare through innovative research and clinical excellence. Situated in the heart of the Austrian Alps, it combines a rich tradition of medical education with cutting-edge scientific inquiry. As a prominent sponsor of clinical trials, the university focuses on a broad spectrum of medical fields, emphasizing the translation of research findings into practical applications for patient care. With a commitment to ethical standards and rigorous methodologies, the Medical University of Innsbruck strives to enhance treatment options and improve health outcomes globally through its collaborative efforts in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Innsbruck, Tirol, Austria
Patients applied
Trial Officials
Wolfgang Dichtl, MD, PhD
Principal Investigator
Medical University Innsbruck
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials